Dosing regimens associated with extended release paliperidone injectable formulations
AssigneeJanssen Pharmaceutica NV
InventorsRuth Milz, Frank Wiegand, Panna Sanga, John Louie
Life of this patent
Estimating the term…
Abstract
The present invention provides a method of treating patients with long acting injectable paliperidone palmitate formulations.
Claims24
A method of stabilizing or decreasing body weight of a patient who has been treated with a paliperidone palmitate extended-release injectable suspension at either one-month intervals (PP1M) or three-month intervals (PP3M), comprising administering a last dose of the PP1M or the PP3M and then administering an initial dose of a paliperidone palmitate extended-release injectable suspension having a six month dosing interval (PP6M), wherein the patient has a body mass index (BMI) of 25 to less than 30 at the time of the initial dose of the PP6M.
Dependencies are inferred from the claim text.